摘要
目的:探究嗜酸乳杆菌联合谷胱甘肽治疗非酒精性脂肪性肝病(NAFLD)的临床应用及安全性。方法:选取2017年5月~2019年5月本院收治的200例NAFLD患者作为研究对象,按照随机数字表法将其分为观察组(嗜酸乳杆菌联合谷胱甘肽治疗)和对照组(谷胱甘肽治疗),各100例。比较两组临床疗效、治疗前和治疗后肝功能指标[谷草转氨酶(AST)、谷丙转氨酶(ALT)、甘油三酯(TG)、血清总胆固醇(TC)]、健康调查简表(SF-36)评分,以及治疗期间不良反应发生情况。结果:观察组总有效率(99.00%)高于对照组(93.00%,P<0.05)。治疗前,两组AST、ALT、TG、TC水平比较无统计学差异(P>0.05);治疗后,观察组AST、ALT、TG、TC水平低于对照组(P<0.05)。治疗前,两组SF-36各项评分比较无统计学差异(P>0.05);治疗后,观察组SF-36各项评分高于对照组(P<0.05)。治疗期间,两组不良反应总发生率比较无统计学差异(P>0.05)。结论:嗜酸乳杆菌联合谷胱甘肽治疗NAFLD,可改善患者肝功能,提升生活质量,疗效确切,且安全性较高,值得应用与推广。
Objective:To explore the clinical application and safety of lactobacillus acidophilus combined with glutathione in the treatment of non-alcoholic fatty liver disease(NAFLD).Methods:200 NAFLD patients treated from May 2017 to May 2019 in our hospital were selected as research subjects.According to random number table,patients were assigned to the observation group(lactobacillus acidophilus combined with glutathione treatment)and the control group(glutathione treatment),100 cases in each group.Clinical effect,liver function indicators[aspartate aminotransferase(AST),alanine transaminase(ALT),triglyceride(TG)and total cholesterol(TC)]and the Mos 36-item Short Form Health Survey(SF-36)scores before and after treatment,and adverse reactions during treatment were compared between the two groups.Results:Total effective rate in the observation group(99.00%)was higher than that in the control group(93.00%,P<0.05).Before treatment,there was no significant difference in AST,ALT,TG and TC levels between the two groups(P>0.05).After treatment,AST,ALT,TG and TC levels in the observation group were lower than those in the control group(P<0.05).Before treatment,there was no significant difference in SF-36 scores between the two groups(P>0.05).After treatment,SF-36 scores in the observation group were higher than those in the control group(P<0.05).During treatment,there was no significant difference in the total incidence rate of adverse event between the two groups(P>0.05).Conclusion:Lactobacillus acidophilus combined with glutathione in the treatment of NAFLD can improve liver function and life quality of patients,with definite curative effect and high safety.It is worthy of application and promotion.
作者
荣爱梅
吴慧丽
RONG Ai-mei;WU Hui-li(Department of Gastroenterology,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou 450052,China)
出处
《中国合理用药探索》
2021年第7期33-36,共4页
Chinese Journal of Rational Drug Use
关键词
谷胱甘肽
嗜酸乳杆菌
非酒精性脂肪肝
肝功能
安全性
glutathione
lactobacillus acidophilus
non-alcoholic fatty liver disease
liver function
safety
作者简介
荣爱梅,女,主治医师,研究方向:消化内科。E-mail:vj8wwm@163.com;通讯作者:吴慧丽,女,主任医师,研究方向:消化内科。E-mail:b1g6mb@163.com。
